Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "De differentiation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
De-differentiation any process in which previously more complex and variegated social arrangements are replaced by less complex patterns, e.g. the reduction of political pluralism under TOTALITARIANISM. (a specifically postmodernist concept referring to) ‘the collapse of the Modernist order of things’.
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
Owner:ABBOTT LAB INC
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
Systems and compositions comprising zotarolimus that are safer, more effective and produce less inflammation than rapamycin and paclitaxel systems are disclosed. Medical devices comprising supporting structures capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating having the therapeutic compounds, including, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
Owner:ABBOTT LAB INC
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC
Medical devices containing rapamycin analogs
InactiveUS20050175660A1Reduce restenosisReduce restenosis rateBiocideOrganic chemistryTherapeutic effectAnti platelet
A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC
Device having hydration inhibitor
InactiveUS20060171984A1Reduce probabilityReduces restenosis in vasculatureBiocideHydroxy compound active ingredientsBeta-CaroteneDepressant
Medical devices comprising an interventional component for delivering multiple beneficial agents in which a hydration inhibitor controls release of at least one beneficial agent from the device. The hydration inhibitor is relatively less hydrophilic than the beneficial agent and preferably is a drug. Suitable beneficial agents include (I) dexamethasone, estradiol, anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipacdemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs, radiopaque markers, beta-carotene, tocopherols, tocotrienols, and antioxidants
Owner:ABBOTT LAB INC
De-differentiation of human cells
InactiveUS20110033931A1Artificial cell constructsArtificially induced pluripotent cellsHuman cellSomatic cell
Methods of de-differentiating somatic cells to an embryonic stem cell state comprising direct delivery of a protein into the somatic cell, wherein the protein effects de-differentiation of the somatic cell to an embryonic stem cell phenotype.
Owner:CHILDRENS HOSPITAL OF ORANGE COUNTY
Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
InactiveUS20060281791A1Increased proliferationSlow and reduce and prevent onsetBiocidePeptide/protein ingredientsTargeted disruptionTissue Grafting
Compositions and methods for increasing proliferation and / or de-differentiation of postmitotic mammalian cardiomyocytes are disclosed to slow, reduce, or prevent the onset of cardiac damage. In addition, the methods and compositions of the invention can used to produce de-differentiated cardiomyocytes, which can then be used in tissue grafting, implantation or transplantation. The invention is based, in part, on the discovery that postmitotic mammalian cardiomyocytes can proliferate as a result of targeted disruption of p38 MAP kinase. p38 inhibition with optional growth factor stimulation can induce cytokinesis in adult cardiomyocytes.
Owner:CHILDRENS MEDICAL CENT CORP
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
InactiveUS7399480B2Reduce probabilityReduces restenosis in vasculatureBiocideOrganic chemistryAnti plateletCytostatic drugs
Owner:ABBOTT LAB INC
Compositions and methods of administering paclitaxel with other drugs using medical devices
Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC
Plant stem cell line derived from quiescent center and method for isolating the same
The present invention relates to a cell line derived from the quiescent center of a plant and a method for isolating the same, more specifically, relates to a quiescent center-derived homogeneous cell line of single-cell origin, which is obtained from the quiescent center of a plant without needing a separate de-differentiation process, and a method for isolating the same.
Owner:UNHWA CORP
Medical devices containing rapamycin analogs
InactiveUS20060198870A1Reduce probabilityReduces restenosis in vasculatureBiocideAntimycoticsAnti plateletAntiproliferative Agents
A medical device comprising a supporting structure having a coating on the surface thereof, the coating containing a therapeutic substance, such as, for example, a drug. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with a drug selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC
In-vitro rapid propagation method for ornithogalum caudatum by taking infant flowers as explants
InactiveCN103931498AIdentical genetic backgroundSame genetic backgroundPlant tissue cultureHorticulture methodsPlant propagationBud
The invention belongs to a flower and plant propagation method and particularly relates an asexual rapid propagation method for flowers and plants. In the asexual rapid propagation method, infant flower base parts of ornithogalum caudatum infant inflorescences are taken as explants for carrying out tissue culture; the de-differentiation rate and the differentiation rate can be up to more than 75%. A callus which is induced by one explant can be subjected to repeated subculture so as to differentiate about 500 cluster buds; the phenotypes of the cluster buds are uniform. The rooting rate of the cluster buds can be up to more than 90% and the transplanting survival rate under a suitable environment is up to 100%. The ornithogalum caudatum can be propagated into plants with completely same genetic backgrounds and ordered appearances in a large scale within a relative short time; the variation of regenerated plants is low; a regeneration system is very efficient; the cost of an average single-plant regenerated seedling is very low; the asexual rapid propagation method is suitable for being used in large-batch, efficient and rapid propagation of the ornithogalum caudatum and is very suitable for being used in industrial production.
Owner:BEIJING UNIV OF AGRI
Medical Devices Containing Rapamycin Analogs
InactiveUS20080145402A1Reduce probabilityReduces restenosis in vasculatureBiocideSurgeryAnti plateletAntiproliferative Agents
A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC
Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions
A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay selected from the group consisting of a lipolysis assay, an assay that measures the amount of glycerol introduced by a cell into a suspension medium of the cell, an adipocyte differentiation assay, an assay that measures the level of the enzyme glycerol-3-phosphate dehydrogenase, an assay that measures the inhibition of differentiation of preadipocytes to adipocytes, an assay that measures the accumulation of lipid in an adipocyte, an assay that measures the de-differentiation of adipocytes into preadipocytes, and combinations thereof. Sclareol and sclareol-like compounds and sclareolide and sclareolide-like compounds are identified as useful in the treatment of overweight and obese conditions and disorders and conditions associated with adipose tissue abnormalities. These compounds can be formulated for oral administration.
Owner:PHYTOMYCO RES CORP
Apparatus and Method for Culturing Cells and Tissue
ActiveUS20140113345A1Delay de-differentiationPromote differentiationBioreactor/fermenter combinationsBiological substance pretreatmentsCulture cellPhysical therapy
An apparatus that provides synchronized chronic electrical stimulation and chronic stretch to a cell culture or tissue. The apparatus includes a programmable controller which synchronizes stretch and electrical stimulation applied to a deformable culture container, such as a silicone rubber culture dish. The apparatus is used to treat cells and retard de-differentiation or promote differentiation and maturation in some applications.
Owner:IONOPTIX
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC
Medical Devices Containing Rapamycin Analogs
InactiveUS20080153790A1Reduce probabilityReduces restenosis in vasculatureBiocideAntimycoticsAnti plateletCytostatic drugs
Owner:ABBOTT LAB INC
Detection method
InactiveUS20090325810A1Nucleotide librariesMicrobiological testing/measurementNormal cellLarge intestine
The present invention relates generally to an array of nucleic acid molecules, the expression profiles of which characterise the anatomical origin of a cell or population of cells within the large intestine. More particularly, the present invention relates to an array of nucleic acid molecules, the expression profiles of which characterise the proximal or distal origin of a cell or population of cells within the large intestine. The expression profiles of the present invention are useful in a range of applications including, but not limited to determining the anatomical origin of a cell or population of cells which have been derived from the large intestine. Still further, since the progression of a normal cell towards a neoplastic state is often characterised by phenotypic de-differentiation, the method of the present invention also provides a means of identifying a cellular abnormality based on the expression of an incorrect expression profile relative to that which should be expressed by the subject cells when considered in light of their anatomical location within the colon. Accordingly, this aspect of the invention provides a valuable means of identifying the existence of large intestine colon cells, these being indicative of an abnormality within the large intestine such as the onset or predisposition to the onset of a condition such as a colorectal neoplasm.
Owner:CLINICAL GENOMICS PTY LTD +1
Method of effecting de-differentiation of a cell
InactiveUS20110165570A1Maintain pluripotencySugar derivativesMicrobiological testing/measurementDe differentiationCell biology
The invention provides a method of effecting de-differentiation of an at least partially differentiated cell or of maintaining pluripotency and / or self-renewing characteristics of an undifferentiated cell. The method comprises increasing the amount or the activity of an Err protein, or a functional fragment thereof, in the cell.
Owner:AGENCY FOR SCI TECH & RES
Anti-Doppler frequency shift synchronization method based on pseudo-random sequence differential coding
ActiveCN108964824ASave resourcesEasy to implementTime-division multiplexMulti-frequency code systemsPeak valueDifferential coding
The invention discloses an anti-Doppler frequency shift synchronization method based on pseudo-random sequence differential coding. The anti-Doppler frequency shift synchronization method can simultaneously realize time and bit timing synchronization in the case of strong Doppler frequency shift, is suitable for a single / multi-carrier system, and comprises the steps of: (1) performing differentialencoding on a pseudo-random sequence at a transmitting end, regarding the pseudo-random sequence after differential encoding as pilots, and maintaining autocorrelation property thereof; (2) performing de-differentiation processing on two orthogonal sampling signals before sliding correlation detection of the receiving end; (3) realizing correlation operation of received signals and local pilot symbols by means of filtering, comparing a correlation peak value output by a filter with a set threshold, and further determining a time synchronization moment; (4) and comparing a signal sequence extracted from different clock skew with a correlation peak of the local pilot, determining the optimal extraction clock, and realizing bit timing synchronization. The anti-Doppler frequency shift synchronization method adopts interceptive m sequences, suppresses the influence of Doppler frequency shift on synchronization through differential encoding, and can apply the pilot sequence to frequency offset and channel estimation, thereby laying a foundation for the subsequent frequency offset compensation and demodulation processing.
Owner:NO 54 INST OF CHINA ELECTRONICS SCI & TECH GRP
Plant stem cell line derived from quiescent center and method for isolating the same
Owner:UNHWA CORP
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
Owner:ABBOTT LAB INC
Cytoplasmic transfer to de-differentiate recipient cells
InactiveUS20130104253A1Alleviates and prevents senescencePromote growthBiocideDiagnosticsCytoplasmic transferActive matter
Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and / or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
Owner:CHAPMAN KAREN B
Detection method
Owner:CLINICAL GENOMICS PTY LTD +1
Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions
A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay selected from the group consisting of a lipolysis assay, an assay that measures the amount of glycerol introduced by a cell into a suspension medium of the cell, an adipocyte differentiation assay, an assay that measures the level of the enzyme glycerol-3-phosphate dehydrogenase, an assay that measures the inhibition of differentiation of preadipocytes to adipocytes, an assay that measures the accumulation of lipid in an adipocyte, an assay that measures the de-differentiation of adipocytes into preadipocytes, and combinations thereof. Sclareol and sclareol-like compounds and sclareolide and sclareolide-like compounds are identified as useful in the treatment of overweight and obese conditions and disorders and conditions associated with adipose tissue abnormalities. These compounds can be formulated for oral administration.
Owner:PHYTOMYCO RES CORP
Method for efficiently acquiring gerbera jamesonii detoxification seedling
InactiveCN105165609AEfficiently obtainedOvercoming more detoxification materialsHorticulture methodsPlant tissue cultureShoot apexBud
The invention discloses a method for efficiently acquiring a gerbera jamesonii detoxification seedling. The method is characterized by comprising the following steps: (1) collecting gerbera jamesonii tender leaves, and de-differentiating the gerbera jamesonii to generate callus; (2) thermally treating the callus, continuously inducing the callus to form adventitious bud, and rooting the adventitious bud to form a strong tissue culture seedling; (3) further stripping a tissue culture seedling stem tip, and de-differentiating to generate callus; (4) thermally treating the callus, and inducing to form a seedling; (5) randomly extracting the tissue culture seedling in the step (4), carrying out the virus detection, if the seedling is qualified in detection, the seedling is the gerbera jamesonmii detoxification seedling, if the seedling is not qualified in the detection, repeating the steps (1) to (4) until the qualified gerbera jamesonii detoxification seedling is acquired. The callus is generated by virtue of the twice de-differentiation, and then the callus is thermally treated and de-differentiated to finally obtain the gerbera jamesonii detoxification seedling, so that the difficulty of the existing detoxification technology such as non-thoroughness in detoxification, complexity in operation and can meet the factory-like detoxification production requirement.
Owner:WUXI NANLIGONG TECH DEV
Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
InactiveUS20110098232A1Exceed capacityImprove leakageCyclic peptide ingredientsAntineoplastic agentsCalcium handlingCalcium influx
Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
Owner:ZEILIG CHARLES E
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com